A Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Telomelysin (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Oncolys BioPharma
- 18 Nov 2014 The first patient has been enrolled, according to an Oncolys BioPharma media release.
- 18 Nov 2014 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018 as reported by ClinicalTrials.gov record.
- 30 Jan 2014 New trial record